drugset / Trial / NCT02238860

A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis

NCT02238860

Phase 4 Unknown 100 enrolled Asian Institute Of Medical Sciences
RandomizedParallel-groupTriple-blindTreatment

Summary

Entacavir and tenofovir are two first line therapies for chronic hepatitis B. Both agents have been claimed equivalent in treatment, there are no head to head trials available in the literature about there effectiveness in HBV Decompensated Cirrhosis. The investigators aimed to compare safety/efficacy and virological response in patients with HBV Decompensated Cirrhosis.

Timeline

Start
2014-09
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Entacavir Unknown 0.5 mg
Comparator Tenofovir Small molecule 300 mg

Indications